FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204607428> ?p ?o ?g. }

• W3204607428 abstract "Arsenic trioxide (ATO) has been used to treat acute promyelocytic leukemia. However, it is not effective in treating solid tumors such as colorectal cancer. We have previously reported that polyploid giant cancer cells (PGCCs) exhibiting the characteristics of cancer stem cells can be generated by various inducers. In this study, ATO was used to induce the formation of PGCCs in LoVo and Hct116 colon cancer cell lines. The migration, invasion, and proliferation abilities of colon cancer cells with and without ATO treatment were assessed by wound-healing, transwell, and plate colony formation assays. The expression of epithelial to mesenchymal transition-related proteins and erythroid differentiation-related proteins in colon cancer cells was further evaluated by western blot and immunocytochemical assays. LoVo and Hct116 cells were transfected with a eukaryotic expression vector for green fluorescent protein (GFP), red fluorescent protein (RFP), H2B-GFP, and H2B-mCherry to study PGCCs formation via cell fusion. WB and ICC assays were performed to assess the expression of cell fusion-related proteins. MG132, small interfering RNA-glial cell missing 1 (GCM1), and chromatin immunoprecipitation-polymerase chain reaction assays were performed to study the role of GCM1/syncytin-1-mediated cell fusion. Clinically, the significance of cell fusion-related proteins and erythroid differentiation-related proteins expression in human colorectal cancer tissues was evaluated. Results of our study showed that ATO induced the formation of PGCCs, and the daughter cells derived from PGCCs gained a mesenchymal phenotype and exhibited strong migration, invasion, and proliferation abilities. PGCCs also produced embryonic hemoglobin-delta and -zeta with strong oxygen-binding ability and erythroid differentiation-related proteins after ATO treatment. In addition, cell fusion was observed during the formation of PGCCs, indicated by the presence of yellow fluorescence via the GCM1/syncytin-1 signaling pathway. Clinically, the expression of cell fusion-related and erythroid differentiation-related proteins gradually increased with the progression of human colorectal cancer tissues. In conclusion, ATO can promote tumor progression by inducing the formation of PGCCs via GCM1/syncytin-1-mediated cell fusion. PGCCs can produce daughter cells with high invasion and migration abilities and embryonic hemoglobin with strong oxygen binding ability, promoting survival of tumor cells in a hypoxic microenvironment." @default.
• W3204607428 created "2021-10-11" @default.
• W3204607428 creator A5006002701 @default.
• W3204607428 creator A5010655034 @default.
• W3204607428 creator A5014300174 @default.
• W3204607428 creator A5015001687 @default.
• W3204607428 creator A5020034543 @default.
• W3204607428 creator A5035324657 @default.
• W3204607428 creator A5049341927 @default.
• W3204607428 creator A5061049387 @default.
• W3204607428 creator A5068216036 @default.
• W3204607428 creator A5078067582 @default.
• W3204607428 date "2021-10-05" @default.
• W3204607428 modified "2023-10-18" @default.
• W3204607428 title "Arsenic Trioxide Promotes Tumor Progression by Inducing the Formation of PGCCs and Embryonic Hemoglobin in Colon Cancer Cells" @default.
• W3204607428 cites W1491910236 @default.
• W3204607428 cites W1492241376 @default.
• W3204607428 cites W1963765620 @default.
• W3204607428 cites W1969206395 @default.
• W3204607428 cites W1972816098 @default.
• W3204607428 cites W1976629222 @default.
• W3204607428 cites W1981499229 @default.
• W3204607428 cites W1984302113 @default.
• W3204607428 cites W1996422107 @default.
• W3204607428 cites W1996467959 @default.
• W3204607428 cites W2009886857 @default.
• W3204607428 cites W2012471677 @default.
• W3204607428 cites W2014707352 @default.
• W3204607428 cites W2044630988 @default.
• W3204607428 cites W2051055358 @default.
• W3204607428 cites W2060631540 @default.
• W3204607428 cites W2061927476 @default.
• W3204607428 cites W2062723127 @default.
• W3204607428 cites W2071534620 @default.
• W3204607428 cites W2089980278 @default.
• W3204607428 cites W2109815830 @default.
• W3204607428 cites W2111504523 @default.
• W3204607428 cites W2115918874 @default.
• W3204607428 cites W2137682169 @default.
• W3204607428 cites W2168458488 @default.
• W3204607428 cites W2196607495 @default.
• W3204607428 cites W2535504455 @default.
• W3204607428 cites W2591231168 @default.
• W3204607428 cites W2603374842 @default.
• W3204607428 cites W2606001457 @default.
• W3204607428 cites W2610143972 @default.
• W3204607428 cites W2803375800 @default.
• W3204607428 cites W2810877455 @default.
• W3204607428 cites W2883768270 @default.
• W3204607428 cites W2883803263 @default.
• W3204607428 cites W2941830556 @default.
• W3204607428 cites W2969133078 @default.
• W3204607428 cites W2971267238 @default.
• W3204607428 cites W2985749341 @default.
• W3204607428 cites W3009020111 @default.
• W3204607428 cites W3135355255 @default.
• W3204607428 doi "https://doi.org/10.3389/fonc.2021.720814" @default.
• W3204607428 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8523995" @default.
• W3204607428 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34676163" @default.
• W3204607428 hasPublicationYear "2021" @default.
• W3204607428 type Work @default.
• W3204607428 sameAs 3204607428 @default.
• W3204607428 citedByCount "15" @default.
• W3204607428 countsByYear W32046074282022 @default.
• W3204607428 countsByYear W32046074282023 @default.
• W3204607428 crossrefType "journal-article" @default.
• W3204607428 hasAuthorship W3204607428A5006002701 @default.
• W3204607428 hasAuthorship W3204607428A5010655034 @default.
• W3204607428 hasAuthorship W3204607428A5014300174 @default.
• W3204607428 hasAuthorship W3204607428A5015001687 @default.
• W3204607428 hasAuthorship W3204607428A5020034543 @default.
• W3204607428 hasAuthorship W3204607428A5035324657 @default.
• W3204607428 hasAuthorship W3204607428A5049341927 @default.
• W3204607428 hasAuthorship W3204607428A5061049387 @default.
• W3204607428 hasAuthorship W3204607428A5068216036 @default.
• W3204607428 hasAuthorship W3204607428A5078067582 @default.
• W3204607428 hasBestOaLocation W32046074281 @default.
• W3204607428 hasConcept C104317684 @default.
• W3204607428 hasConcept C107459253 @default.
• W3204607428 hasConcept C121608353 @default.
• W3204607428 hasConcept C145103041 @default.
• W3204607428 hasConcept C1491633281 @default.
• W3204607428 hasConcept C153911025 @default.
• W3204607428 hasConcept C207701140 @default.
• W3204607428 hasConcept C2779013556 @default.
• W3204607428 hasConcept C28328180 @default.
• W3204607428 hasConcept C502942594 @default.
• W3204607428 hasConcept C54355233 @default.
• W3204607428 hasConcept C55427017 @default.
• W3204607428 hasConcept C55493867 @default.
• W3204607428 hasConcept C76419328 @default.
• W3204607428 hasConcept C86803240 @default.
• W3204607428 hasConcept C92488253 @default.
• W3204607428 hasConcept C95444343 @default.
• W3204607428 hasConcept C96232424 @default.
• W3204607428 hasConceptScore W3204607428C104317684 @default.
• W3204607428 hasConceptScore W3204607428C107459253 @default.
• W3204607428 hasConceptScore W3204607428C121608353 @default.
• W3204607428 hasConceptScore W3204607428C145103041 @default.
• W3204607428 hasConceptScore W3204607428C1491633281 @default.

• next